Kristi Bose
Psychiatric/Mental Health · Omaha, NENPI 1336680396
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,305 of the $13,382 with a category attached, or 69.5%. 29 manufacturers reported payments, led by Johnson & Johnson at 35.6% of the total. Reporting peaked in 2022 at $6,721 and has fallen 83.8% since, to $1,088 in 2025. Among psychiatric/mental health clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 578 payments — averaging $23.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$886
- Sunovion Pharmaceuticals Inc.$667
- Alkermes, Inc.$610
- plus $4K from 23 others
What the payments were for
- Consulting fees$3,18024%
- Travel & lodging$7365%
- Food & beverage$9,30570%
- Education$1621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 45 | $4,761 |
| AbbVie | 121 | $1,785 |
| Otsuka America Pharmaceutical, Inc. | 62 | $1,012 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 60 | $886 |
| Sunovion Pharmaceuticals Inc. | 36 | $667 |
| Alkermes, Inc. | 45 | $610 |
| Lundbeck LLC | 39 | $609 |
| Supernus Pharmaceuticals, Inc. | 29 | $590 |
| Teva Pharmaceuticals USA, Inc. | 21 | $486 |
| Neos Therapeutics, LP | 32 | $275 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $226 |
| Axsome Therapeutics, Inc. | 13 | $195 |
| Corium, LLC | 12 | $163 |
| Tris Pharma Inc | 8 | $157 |
| Vanda Pharmaceuticals Inc. | 6 | $157 |
| Idorsia Pharmaceuticals US Inc | 6 | $142 |
| Janssen Scientific Affairs, LLC | 1 | $140 |
| E.r. Squibb & Sons, L.L.C. | 5 | $90 |
| Ironshore Pharmaceuticals Inc. | 4 | $63 |
| Adlon Therapeutics L.p. | 3 | $53 |
| Merck | 4 | $53 |
| Collegium Pharmaceutical, Inc. | 3 | $51 |
| Noven Therapeutics, LLC | 3 | $48 |
| Bausch Health US, LLC | 2 | $42 |
| Almatica Pharma LLC | 2 | $39 |
| Harmony Biosciences LLC | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Eisai Inc. | 1 | $15 |
| Brainsway USA Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,382 in reported general payments places this provider in the 95th percentile of 255 psychiatric/mental health providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 61 | $146,966 |
| CaplytaLumateperone Tosylate | 13 | $23,203 |
| Methylphenidate ErMethylphenidate Hcl | 20 | $2,445 |
| Vilazodone Hcl | 13 | $1,449 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $744 |
| Gabapentin | 27 | $483 |
| Lamotrigine | 17 | $408 |
| Clonazepam | 16 | $71 |
| Alprazolam | 12 | $11 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $4,761 | $146,96661 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $886 | $23,20313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Omaha
- Janelle HillOmaha$24K
- Robert LundholmOmaha$12K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Julie ZulkoskyOmaha$8K
- John RamseyOmaha$8K
- M Joyce SasseOmaha$7K
- Molly PetersenOmaha$6K
- Salina AndersonOmaha$6K
- Heather WilhelmOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.